Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASH 2018: ECHELON-2 trial

Prof. Lorenz Trümper about the ECHELON-2 trial.

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congress news 11/12/2018

ASH 2018: Highlights lymphoma

Dr. Martin Hutchings from Denmark talks about the first in-human trial he presented at ASH 2018 and mentions another congress highlight: the ECHELON-2 trial.

Congress news 11/12/2018

ASH 2018: ACT 1-2

Presenter Francesco d'Amore summarizes the final results of the ACT-1/2 trial.

Congress news 11/12/2018

ASH 2018: AUGMENT trial

Prof. John Leonard highlights data from the AUGMENT trial as presented on ASH 2018. AUGMENT is a phase 3, multicenter, randomized trial of lenalidomide plus rituximab (R2) versus placebo plus rituximab was conducted in patients with R/R indolent non-Hodgkin lymphoma.

Congress news 11/12/2014

ASH 2014 Interview Dr. Saad Usmani

New developments in cytogenetic testing of Multiple Myeloma patients While multiple myeloma is an incurable disease, the prognosis of patients can vary greatly because of the genetic heterogeneity of the disease. The genetic profile of the malignant cells influences, amongst other things, the response to treatment. In this video, Dr. Saad Usmani will explain to us how the cytogenetic profile is currently determined and what the future will bring us. He will also discuss a new development in this field, the MMProfiler.

Congress news 08/12/2014

ASH 2014 Highlight 3 - Leukemia

Highlight on leukemia: Prof. Dr. med. Uwe Platzbecker tells if ATRA+arsenicumtrioxide should become the new standard care for non-high risk APML by illustrating the Italian-German APL0406 trial. Ian Flinn MD PhD provides an overview on novel therapies for CLL. Prof. Dr. Michele Baccarani discusses whether imatinib remains the standard therapy for CML by elaborating on the DASISION, SPIRIT-2 and EPIC trails. Prof. Dr. Rien van Oers concludes with the PROLONG trial which investigates ofatumumab maintenance therapy in R/R CLL.